Publicaciones en colaboración con investigadores/as de Mayo Clinic (22)

2023

  1. Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes

    Human molecular genetics, Vol. 32, Núm. 16, pp. 2646-2655

2022

  1. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604

  2. Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex

    Journal of Hepatology, Vol. 76, Núm. 4, pp. 921-933

2021

  1. Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis

    Gastroenterology, Vol. 160, Núm. 3, pp. 889-905.e10

  2. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  2. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

2018

  1. Cholangiocytes in health and disease: From basic science to novel treatments

    Biochimica et Biophysica Acta - Molecular Basis of Disease

  2. MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma

    Hepatology, Vol. 68, Núm. 2, pp. 561-573

  3. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2017

  1. New potential targets for the treatment of biliary diseases

    Current Drug Targets

  2. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

  3. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

    Hepatology, Vol. 66, Núm. 4, pp. 1125-1143

2016

  1. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease

    American Journal of Human Genetics, Vol. 98, Núm. 6, pp. 1193-1207

2015

  1. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease

    Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961

2014

  1. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression

    American Journal of Pathology, Vol. 184, Núm. 1, pp. 110-121

  2. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

    Gut, Vol. 63, Núm. 10, pp. 1658-1667

2013

  1. Alcohol consumption on pancreatic diseases

    World Journal of Gastroenterology, Vol. 19, Núm. 5, pp. 638-647

  2. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases

    Hepatology, Vol. 58, Núm. 1, pp. 409-421

2012

  1. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease

    Gastroenterology, Vol. 142, Núm. 3, pp. 622-633.e4